US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyntra Bio Inc

7.67

+0.14951.99%

Volume:6K

Turnover:43.42K

Market Cap:31.03M

PE:0.17

High:7.74

Open:7.67

Low:7.67

Close:7.52

52wk High:12.60

52wk Low:6.32

Shares:4.05M

Float Shares:3.56M

Volume Ratio:0.90

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):45.27

EPS(LYR):45.37

ROE:--

ROA:-22.50%

PB:-1.03

PE(LYR):0.17

Loading ...

Overview Company News Filings

Kyntra Bio initiated with a Buy at Rodman & Renshaw

Fluidra appoints Juan Graham CFO, succeeding Xavier Tintoré

Kyntra Bio CEO Thane Wettig buys 2,800 shares worth $19,852

Kyntra Bio Warned of Nasdaq Non‑Compliance, Faces Delisting Risk Without Remediation Plan by May 18, 2026

Kyntra Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Kyntra Bio Q1 net loss narrows to $15.1 million; revenue rises to $3.7 million

Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY

Benzinga Earnings

BRIEF-Kyntra Bio Inc Q1 Net Income USD -15.198 Million

Kyntra Bio Inc Q1 Revenue From Cont Ops USD 3.7 Million

THOMSON REUTERS

Press Release: Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Kyntra Bio Inc expected to post a loss of $3.35 a share - Earnings Preview

Kyntra Bio to report first-quarter 2026 financial results after market close

Kyntra Bio gets Nasdaq notice for failing $50 million assets and revenue listing rule

Kyntra Bio to present at Needham Virtual Healthcare Conference

Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale

Kyntra Bio Q4 2025 net loss rises 67.97% to USD 14.6 million as revenue falls 59.25% to USD 1.28 million

Kyntra Bio Inc - Phase 2 FG-3246 Trial in Mcrpc Enrolling, Interim Analysis Expected 2H 2026

THOMSON REUTERS

Kyntra Bio Inc - Q4 EPS $-3.51

THOMSON REUTERS

Press Release: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Kyntra Bio Inc expected to post a loss of $3.88 a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/KYNB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYNB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","market":"US","secType":"STK","nameCN":"Kyntra Bio Inc","latestPrice":7.6695,"timestamp":1787583526890,"preClose":7.52,"halted":0,"volume":5647,"delay":0,"changeRate":0.019880319148936256,"floatShares":3561200,"shares":4045445,"eps":45.266125,"marketStatus":"Trading","change":0.1495,"latestTime":"08-24 11:09:56 EDT","open":7.67,"high":7.74,"low":7.6695,"amount":43418.0889,"amplitude":0.009375,"askPrice":7.7,"askSize":295,"bidPrice":7.62,"bidSize":20,"shortable":3,"etf":0,"ttmEps":45.266125,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":7.52,"preHourTrading":{"tag":"盘前","latestPrice":7.69,"preClose":7.52,"latestTime":"08:42 EDT","volume":10,"amount":76.9,"timestamp":1787575320174,"change":0.17,"changeRate":0.022606,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":7.52,"preClose":7.52,"latestTime":"19:30 EDT","volume":60,"amount":458.4146,"timestamp":1787355005170,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.900645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","floatShares":3561200,"roa":"-22.50%","roe":"--","lyrEps":45.371456,"volumeRatio":0.900645,"shares":4045445,"dividePrice":0,"high":7.74,"amplitude":0.009375,"preClose":7.52,"low":7.6695,"week52Low":6.32,"pbRate":"-1.03","psRate":"6.72","week52High":12.6,"institutionHeld":0,"latestPrice":7.6695,"committee":-0.873016,"eps":45.266125,"divideRate":0,"volume":5647,"delay":0,"ttmEps":45.266125,"open":7.67,"prevYearClose":8.78,"prevWeekClose":7.52,"prevMonthClose":6.73,"prevQuarterClose":7.55,"fiveDayClose":6.81,"twentyDayClose":7.05,"sixtyDayClose":7.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYNB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"KYNB","fiscalQuarterEnding":"2026/06","expectedEps":-3.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-4.68},{"market":"US","date":"2026-05-11","symbol":"KYNB","fiscalQuarterEnding":"2026/03","expectedEps":-3.36,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-3.74},{"market":"US","date":"2026-03-16","symbol":"KYNB","fiscalQuarterEnding":"2025/12","expectedEps":-3.89,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"post","actualEps":-3.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYNB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYNB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1783396800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYNB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYNB","date":"2026-08-21","current":0.166129,"percent":0.487013,"low":0.128311,"twenty":0.149739,"median":0.162522,"eighty":0.173439,"high":0.188779,"avg":0.161409,"sd":0.014739,"marketCap":29639587},"quantilePoints":[{"date":"2026-01-09","current":0.17821,"twenty":0.178998,"median":0.18018,"eighty":0.181362,"marketCap":38431727},{"date":"2026-01-16","current":0.170144,"twenty":0.170369,"median":0.172958,"eighty":0.17821,"marketCap":36692186},{"date":"2026-01-23","current":0.168268,"twenty":0.168268,"median":0.171269,"eighty":0.17821,"marketCap":36287641},{"date":"2026-01-30","current":0.150259,"twenty":0.160389,"median":0.169206,"eighty":0.172958,"marketCap":32404014},{"date":"2026-02-06","current":0.140692,"twenty":0.153073,"median":0.163953,"eighty":0.171457,"marketCap":30340837},{"date":"2026-02-13","current":0.140317,"twenty":0.147445,"median":0.160201,"eighty":0.171269,"marketCap":30259928},{"date":"2026-02-20","current":0.14707,"twenty":0.146282,"median":0.158795,"eighty":0.170369,"marketCap":31716288},{"date":"2026-02-27","current":0.13075,"twenty":0.144894,"median":0.154199,"eighty":0.170144,"marketCap":28196751},{"date":"2026-03-06","current":0.129155,"twenty":0.137315,"median":0.150635,"eighty":0.168643,"marketCap":27852888},{"date":"2026-03-13","current":0.131688,"twenty":0.133714,"median":0.147445,"eighty":0.165191,"marketCap":28399023},{"date":"2026-03-20","current":0.161033,"twenty":0.133301,"median":0.147633,"eighty":0.164047,"marketCap":29541837},{"date":"2026-03-27","current":0.144268,"twenty":0.133714,"median":0.1489,"eighty":0.163953,"marketCap":26466248},{"date":"2026-04-02","current":0.156621,"twenty":0.135327,"median":0.1489,"eighty":0.163094,"marketCap":28732471},{"date":"2026-04-10","current":0.158607,"twenty":0.13649,"median":0.150021,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-17","current":0.158607,"twenty":0.137128,"median":0.152651,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-24","current":0.154658,"twenty":0.137616,"median":0.154087,"eighty":0.16165,"marketCap":28372304},{"date":"2026-05-01","current":0.160371,"twenty":0.138929,"median":0.154658,"eighty":0.161209,"marketCap":29420432},{"date":"2026-05-08","current":0.156671,"twenty":0.140092,"median":0.155492,"eighty":0.161033,"marketCap":28741595},{"date":"2026-05-15","current":0.173439,"twenty":0.140542,"median":0.155518,"eighty":0.16165,"marketCap":28377265},{"date":"2026-05-22","current":0.171707,"twenty":0.141779,"median":0.155761,"eighty":0.163953,"marketCap":28093897},{"date":"2026-05-29","current":0.173687,"twenty":0.143209,"median":0.156128,"eighty":0.168258,"marketCap":28417746},{"date":"2026-06-05","current":0.168491,"twenty":0.144709,"median":0.156621,"eighty":0.168887,"marketCap":27567642},{"date":"2026-06-12","current":0.167254,"twenty":0.145601,"median":0.156867,"eighty":0.168639,"marketCap":27365237},{"date":"2026-06-18","current":0.170965,"twenty":0.145982,"median":0.157197,"eighty":0.169431,"marketCap":27972453},{"date":"2026-06-26","current":0.171707,"twenty":0.14617,"median":0.158138,"eighty":0.170144,"marketCap":28093897},{"date":"2026-07-02","current":0.1868,"twenty":0.14632,"median":0.158607,"eighty":0.170718,"marketCap":30563245},{"date":"2026-07-10","current":0.181109,"twenty":0.146883,"median":0.158743,"eighty":0.171457,"marketCap":29632179},{"date":"2026-07-17","current":0.182841,"twenty":0.14707,"median":0.160014,"eighty":0.171955,"marketCap":29915547},{"date":"2026-07-24","current":0.174924,"twenty":0.147445,"median":0.160711,"eighty":0.173192,"marketCap":28620151},{"date":"2026-07-31","current":0.167996,"twenty":0.147746,"median":0.161253,"eighty":0.173241,"marketCap":27486680},{"date":"2026-08-07","current":0.172709,"twenty":0.148684,"median":0.162522,"eighty":0.173005,"marketCap":28257845},{"date":"2026-08-14","current":0.174182,"twenty":0.14943,"median":0.163953,"eighty":0.173489,"marketCap":28498708},{"date":"2026-08-21","current":0.161795,"twenty":0.149739,"median":0.162522,"eighty":0.173439,"marketCap":29639587}],"updateTime":1787576605570},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYNB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642846289","title":"Kyntra Bio initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2642846289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642846289?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:16","pubTimestamp":1781003807,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $30 price target The company has a first-in-class CD46-targeting ant...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyntra-bio-initiated-with-a-buy-at-rodman-renshaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyntra-bio-initiated-with-a-buy-at-rodman-renshaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638389650","title":"Fluidra appoints Juan Graham CFO, succeeding Xavier Tintoré","url":"https://stock-news.laohu8.com/highlight/detail?id=2638389650","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638389650?lang=en_us&edition=fundamental","pubTime":"2026-05-28 14:37","pubTimestamp":1779950268,"startTime":"0","endTime":"0","summary":"Fluidra appointed Juan Graham as chief financial officer, effective June 1, 2026.Outgoing CFO Xavier Tintoré will step down on Aug. 1, 2026, remaining through year-end to support the transition.Graham brings 25+ years in senior finance roles, including nearly two decades at Johnson & Johnson.He most recently served as CFO at U.S.-listed FibroGen, later at Perspective Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fluidra SA published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL4BpCCw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU2129689431.USD","LU0795875086.SGD","LU1023059063.AUD","BK4504","LU1066051225.USD","LU0124676726.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","LU1066053197.SGD","LU0114720955.EUR","LU2430703178.SGD","IE00BN8TJ469.HKD","LU0820562030.AUD","LU1043141123.HKD","LU1506573853.SGD","IE00B3PB1722.GBP","LU1983299246.USD","IE00B42XCP33.USD","LU2456880835.USD","LU1778281490.HKD","IE00BDGV0183.EUR","IE000SO60NU8.SGD","IE00BLSP4239.USD","LU0426417589.USD","LU0792757196.USD","LU0964807845.USD","LU1551013342.USD","IE00BFXG1179.USD","IE00BGHQF631.EUR","BK4568","LU0943347566.SGD","LU2471134879.HKD","LU0345770308.USD","LU0098860793.USD","LU1496350502.SGD","JNJ","KYNB","IE000MB6IJN5.SGD","BK4588","LU2403377893.USD","BK4532","LU1228905540.USD","IE0034235303.USD","LU2505996681.GBP","BK4534","BK4550","LU1732799900.SGD","IE0001KFT4U8.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078719","title":"Kyntra Bio CEO Thane Wettig buys 2,800 shares worth $19,852","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078719","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078719?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105650,"startTime":"0","endTime":"0","summary":"Thane Wettig, CEO and director, reported the purchase of 2,800 Kyntra Bio common shares at USD 7.09.The filing also listed 40 shares held indirectly by a spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL2KTX85:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Kyntra Bio CEO Thane Wettig buys 2,800 shares worth $19,852","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635760802","title":"Kyntra Bio Warned of Nasdaq Non‑Compliance, Faces Delisting Risk Without Remediation Plan by May 18, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635760802","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635760802?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:01","pubTimestamp":1778738475,"startTime":"0","endTime":"0","summary":"Kyntra Bio, Inc. (KYNB) has disclosed a new risk, in the Share Price & Shareholder Rights category. Kyntra Bio, Inc. faces a significant listing ri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kyntra-bio-warned-of-nasdaq-non‑compliance-faces-delisting-risk-without-remediation-plan-by-may-18-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kyntra-bio-warned-of-nasdaq-non‑compliance-faces-delisting-risk-without-remediation-plan-by-may-18-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258122","title":"Kyntra Bio Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258122","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258122?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:02","pubTimestamp":1778533368,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc reports results for the quarter ended March 31 - Earnings SummaryKyntra Bio Inc KYNB.OQ reported a quarterly adjusted loss of $3.76 per share for the quarter ended March 31, lower than ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634823207","title":"Kyntra Bio Q1 net loss narrows to $15.1 million; revenue rises to $3.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634823207","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634823207?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:09","pubTimestamp":1778530172,"startTime":"0","endTime":"0","summary":"Kyntra Bio posted Q1 2026 revenue of USD 3.74 million, up 36.5% year over year, while net loss from continuing operations narrowed to USD 15.1 million.Loss per share from continuing operations improved to USD 3.74, from USD 4.15 a year earlier.Cash, cash equivalents, investments, and accounts receivable totaled USD 100.3 million at March 31, supporting cash runway into 2028.Phase 2 FG-3246 monotherapy trial in metastatic castration-resistant prostate cancer remained on track for interim analysis in 4Q 2026.Protocol for pivotal Phase 3 roxadustat trial in lower-risk MDS anemia with high transfusion burden is being finalized following FDA feedback, with trial initiation targeted for second half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL4y09YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","KYNB","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014039.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634732232","title":"Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2634732232","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634732232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:09","pubTimestamp":1778530146,"startTime":"0","endTime":"0","summary":"Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent decrease over earnings of $1.15 per share from the same period last year.  The company reported $3.738 million in sales","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52468251/kyntra-bio-q1-eps-3-76-down-from-1-15-yoy-sales-3-738m-up-from-2-739m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634286232","title":"BRIEF-Kyntra Bio Inc Q1 Net Income USD -15.198 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634286232","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634286232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529948,"startTime":"0","endTime":"0","summary":"BRIEF-Kyntra Bio Inc Q1 Net Income USD -15.198 Million\n\n\nMay 11 (Reuters) - Kyntra Bio Inc Q1 net income from cont ops USD -15.1 million.\n\nQ1 revenue from cont ops USD 3.7 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nPLX4E0ECE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634329362","title":"Kyntra Bio Inc Q1 Revenue From Cont Ops USD 3.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634329362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634329362?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529903,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nPLX4E0ECE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYNB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232793","title":"Press Release: Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232793","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232793?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529900,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer  is progressing well with the interim analysis. -- Positive results from the investigator-sponsored study of FG-3246 in. combination with enzalutamide in patients with mCRPC were presented at. ASCO GU in February 2026, further validating key Phase 2 monotherapy. -- Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia. in patients with lower-risk myelodysplastic syndromes  and high. -- Kyntra Bio to host conference call and webcast presentation today at 5:00. Key Highlights of First Quarter, Recent Developments, and Upcoming Milestones. targeting CD46, in mCRPC is actively enrolling and remains on track for. -- Higher tumor uptake of FG-3180 was numerically associated with","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800965.SGD","BK4504","BK4231","LU2236285917.USD","LU0128525689.USD","LU1267930227.SGD","R","BK4232","BK4099","ADC","03160","BK4604","BK4022","BK4139","LU0211327993.USD","BK4555","TM","LU0211328371.USD","LU0310799852.SGD","BK4588","BK4585","LU0052756011.USD","BK4109","BK4080","KYNB","LU1267930490.SGD","DD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634717462","title":"Kyntra Bio Inc  expected to post a loss of $3.35 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634717462","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634717462?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:49","pubTimestamp":1778273345,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc  expected to post a loss of $3.35 a share - Earnings Preview Kyntra Bio Inc KYNB.OQ KYNB.O is expected to  show a fall in quarterly revenue when it reports  results on May 11 for the pe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633659039","title":"Kyntra Bio to report first-quarter 2026 financial results after market close","url":"https://stock-news.laohu8.com/highlight/detail?id=2633659039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633659039?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:11","pubTimestamp":1777925480,"startTime":"0","endTime":"0","summary":"Kyntra Bio schedules Q1 2026 financial results release for May 11.Conference call set for May 11 at 5:00 p.m. ET, with live webcast available here.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL3RK267:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","KYNB","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626306671","title":"Kyntra Bio gets Nasdaq notice for failing $50 million assets and revenue listing rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2626306671","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626306671?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:13","pubTimestamp":1775765628,"startTime":"0","endTime":"0","summary":"Nasdaq notified Kyntra Bio on April 2, 2026 that it no longer meets Nasdaq Global Select Market continued listing requirement under Rule 5450 tied to $50 million in total assets and total revenue for fiscal 2025.Non-compliance stems from FibroGen International revenue being reported as held for sale in discontinued operations in 2024 and 2025.Listing remains in place for now, with 45 days until May 18, 2026 to submit compliance plan.Nasdaq can grant extension of up to 180 days to regain compliance, setting deadline of Sept. 29, 2026 if plan is accepted.Kyntra Bio may seek transfer to Nasdaq Capital Market as alternative path to maintain a Nasdaq listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the origi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL5VYxzq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1078025761.USD","AZN.UK","LU0029864427.USD","LU0158827948.USD","IE00B4R5TH58.HKD","LU0823416689.USD","LU0052756011.USD","LU0997586432.USD","LU1046234339.USD","LU0972486137.USD","LU1814569148.SGD","LU0557290698.USD","LU1880407132.USD","LU0823399737.USD","LU0128525689.USD","LU2539964713.USD","LU1989772923.USD","LU1273509221.SGD","LU0432979614.USD","LU0889566641.SGD","LU1989771016.USD","03165","LU0211327993.USD","LU1989772840.SGD","LU1291159041.SGD","LU2108987350.USD","LU1196032939.SGD","LU1170363599.USD","LU0792757196.USD","LU0345777659.USD","LU0889565080.SGD","KYNB","LU0171293334.USD","LU1019634622.SGD","LU0997586515.USD","LU1003076772.USD","LU0963555726.SGD","LU1267930227.SGD","LU0289739699.SGD","LU0969580561.USD","LU0960981461.USD","LU0047473722.SGD","LU1051770623.HKD","LU1104425308.USD","LU0496365809.HKD","IE00BFTCPJ56.SGD","IE0034235188.USD","LU0784384876.USD","LU1983299246.USD","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626592288","title":"Kyntra Bio to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626592288","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626592288?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:09","pubTimestamp":1775678981,"startTime":"0","endTime":"0","summary":"Kyntra Bio to present at 25th Annual Needham Virtual Healthcare Conference on April 13-16, 2026.CEO Thane Wettig scheduled to deliver company presentation on April 13, 2026 at 1:30 PM EDT.Management team to hold one-on-one investor meetings during conference.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL77Sk1W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","BK4139","SG9999014039.USD","SG9999014021.USD","BK4588","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2210149790.SGD","KYNB","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620491310","title":"Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491310","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491310?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:25","pubTimestamp":1773692757,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale. Kyntra Bio said it completed the sale of its FibroGen China business to AstraZeneca for about USD 220 million and repaid a term loan to Morgan Stanley Tactical Value. The company said its cash runway has been extended into 2028. Kyntra Bio highlighted FG-3246, a CD46-targeting antibody-drug conjugate, and FG-3180, a PET imaging agent, with a Phase 2 monotherapy trial in metastatic castration-resistant prostate cancer enrolling and interim results expected in 2H 2026. It also said it submitted a final Phase 3 protocol to the FDA for roxadustat in anemia of lower-risk myelodysplastic syndromes, with a potential Phase 3 initiation in 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL2DcCGh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU1481600234.SGD","LU0499090636.EUR","SG9999001176.USD","LU0957799991.USD","LU2089284900.SGD","LU2293690082.USD","SG9999013999.USD","LU0784383803.USD","LU0823399737.USD","LU1989772840.SGD","LU0661504455.SGD","LU2114397693.USD","LU0211326839.USD","SG9999001176.SGD","LU1880407132.USD","AZN.UK","IE00BFTCPJ56.SGD","LU0827474353.SGD","LU1989771016.USD","LU0708994859.HKD","LU0823416689.USD","LU1291159041.SGD","LU1880407215.USD","LU1267930813.SGD","03165","LU1104425308.USD","LU1119994496.HKD","LU1323610961.USD","LU0976567544.SGD","LU0345777147.USD","LU0889566641.SGD","LU0784385840.USD","LU0158827948.USD","LU1989772923.USD","LU0553294199.USD","LU0052756011.USD","LU0289739699.SGD","LU0203347892.USD","LU0526926950.USD","LU1064927863.SGD","LU1057294990.SGD","LU2279689827.SGD","LU0128525929.USD","KYNB","LU0784384876.USD","LU1046234339.USD","LU0757432116.USD","LU1301847155.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620949987","title":"Kyntra Bio Q4 2025 net loss rises 67.97% to USD 14.6 million as revenue falls 59.25% to USD 1.28 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620949987","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620949987?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:03","pubTimestamp":1773691392,"startTime":"0","endTime":"0","summary":"Kyntra Bio published a fourth-quarter and full-year 2025 earnings press release. Q4 total revenue from continuing operations fell 59.2% to USD 1.28 million, and net loss from continuing operations widened 68.4% to USD 14.61 million. For FY 2025, total revenue from continuing operations fell 78.3% to USD 6.44 million, while net loss from continuing operations narrowed 62% to USD 58.2 million. Cash, cash equivalents, investments, and accounts receivable totaled USD 109.4 million at Dec. 31, and the company said this is expected to fund operating plans into 2028. Kyntra said its Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer is actively enrolling with interim analysis planned for 2H 2026, and it submitted the Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes with a target to start the trial in 2H 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL62CBBq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4585","BK4112","LU2210149790.SGD","KYNB","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620998404","title":"Kyntra Bio Inc - Phase 2 FG-3246 Trial in Mcrpc Enrolling, Interim Analysis Expected 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620998404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620998404?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:02","pubTimestamp":1773691320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA7TCB6L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620499533","title":"Kyntra Bio Inc - Q4 EPS $-3.51","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499533?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:02","pubTimestamp":1773691320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA7TCB6L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620870499","title":"Press Release: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620870499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620870499?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:02","pubTimestamp":1773691320,"startTime":"0","endTime":"0","summary":"-- Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody. prostate cancer  is actively enrolling and remains on track for. -- Positive results from the investigator-sponsored study of FG-3246 in. combination with enzalutamide in patients with mCRPC, further validating. key Phase 2 monotherapy design elements, were presented at the 2026 ASCO. \"The encouraging results from the investigator-sponsored combination trial of FG-3246 with enzalutamide provide us with valuable insights and reinforce key design elements in our Phase 2 monotherapy study,\" said Thane Wettig, Chief Executive Officer of Kyntra Bio. \"Our Phase 2 monotherapy trial of FG-3246 is progressing as planned, with interim results expected in the second half of 2026. Additionally, we have submitted the Phase 3 trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and expect feedback from the FDA shortly, with the intention to start a Phase 3 trial in the second half of 2026. With","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310799852.SGD","BK4109","BK4232","03160","BK4231","LU1267930227.SGD","LU0211328371.USD","BK4022","BK4099","TM","LU2236285917.USD","LU1267930490.SGD","BK4604","BK4139","R","LU0310800965.SGD","BK4555","LU0128525689.USD","BK4585","ADC","BK4080","BK4588","BK4504","DD","LU0052756011.USD","KYNB","LU0211327993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619110929","title":"Kyntra Bio Inc  expected to post a loss of $3.88 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619110929","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619110929?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:07","pubTimestamp":1773432456,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc  expected to post a loss of $3.88 a share - Earnings Preview Kyntra Bio Inc KYNB.OQ KYNB.O is expected to  show a fall in quarterly revenue when it reports  results on March 16 for the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N40120J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}]}}